Please provide your email address to receive an email when new articles are posted on . Combined cataract surgery with iStent inject significantly reduced medication burden in patients with glaucoma.

MRI Information: The iStent inject W is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted 510(k) clearance for the iStent infinite trabecular micro-bypass system to reduce IOP as a stand ...

Glaukos received FDA approval for its first-generation MIGS device, the iStent, in 2012. Its second-generation iStent inject, approved by the FDA in 2018, includes two stents preloaded in an ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

Optometrist Dr. David Kordish often talks to patients about glaucoma and cataracts in doing general eye care. Now, he can see his patients with clearer vision and freedom from glaucoma medication ...

SLT is emerging as a cost-effective first-line treatment, offering superior intraocular pressure stability compared to traditional eye drops. Minimally invasive glaucoma surgeries, like the iStent ...

Needham expects Glaukos Corp GKOS to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside is ...

On a hilltop overlooking Camp Pendleton, some of the world’s smallest medical devices are being made. About 225 employees of Glaukos Corp. (NYSE: GKOS) peer into microscopes, constructing daily ...

Glaukos secured a new FDA clearance for its miniaturized stent system designed for glaucoma to help drain the inner eye of built-up fluids and normalize intraocular pressure. The company had received ...

Glaukos has claimed a series of regulatory clearances in Europe for its micro-scale surgical implants to treat patients with glaucoma, expanding the company’s reach overseas. The green lights under ...